Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
Completed
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 4
2005-06-01
The purpose of this research study is to help in the development of safe, effective and
reversible male contraception. We are examining the impact of the drug Miglustat on sperm
production in normal men.
We want to see if Miglustat will inhibit sperm production in men and act as a reversible male
contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of
sperm production. We believe Miglustat may have some potential as a safe, reversible male
contraceptive.
Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)
Completed
University of Washington
Phase 4
2005-06-01
The purpose of this research study is to help in the development of safe, effective and
reversible male contraception. We are examining the impact of the drug Miglustat on sperm
production in normal men.
We want to see if Miglustat will inhibit sperm production in men and act as a reversible male
contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of
sperm production. We believe Miglustat may have some potential as a safe, reversible male
contraceptive.
Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease
Completed
Actelion
Phase 3
2006-02-01
Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher
disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are
required to establish the long term efficacy, safety and tolerability of miglustat in
maintaining diseases stability after a switch from ERT.
This preview shows a limited data set Subscribe for full access, or try a Trial
Miglustat: Clinical Trials Update, Market Analysis, and Future Projections
Last updated: January 27, 2026
Executive Summary
Miglustat (marketed as Zavesca®) is an orally active substrate reduction therapy approved for treating Gaucher disease type 1 and Niemann-Pick disease type C (NPC). Developed by Actelion Pharmaceuticals, now part of Johnson & Johnson, Miglustat has established a niche in rare lysosomal storage disorders. This analysis provides an update on ongoing and completed clinical trials, evaluates current market dynamics, and projects future growth based on scientific, regulatory, and commercial factors.
What is the Current Status of Clinical Trials Involving Miglustat?
Recent and Ongoing Clinical Trials Overview
Trial Phase
Number of Trials
Primary Focus
Key Developments
Status
Phase 1-2
3
Safety, dose optimization for NPC
Confirmed tolerability; explored higher doses
Complete/ongoing
Phase 3
2
Efficacy in rare indications
Recruitment in progress; endpoints include neurological outcomes
Recruiting
Observational
4
Long-term safety and real-world efficacy
Extended follow-up of existing patient cohorts
Ongoing
Investigational
3
Novel formulations (e.g., nasal, inhalational)
Preclinical studies; preparing for Phase 1 trials
Preclinical/Preparation
Key Clinical Trials and Publications
NCT03470412: A Phase 2 trial evaluating Miglustat in NPC patients (completed) demonstrated stabilization in neurological function with manageable side effects, primarily diarrhea and weight loss (Brouwer et al., 2021).
NCT03796112: Expanded access study for Miglustat in pediatric NPC cases ongoing, aiming to assess long-term safety.
Recent Publications: Indicated that genetic stratification may influence drug response, highlighting the need for personalized therapy (Mann et al., 2022).
Regulatory Updates
FDA: Miglustat remains an approved therapy for NPC in the U.S., with ongoing discussions for label expansion.
EMA: Approved for Niemann-Pick disease type C since 2010, with periodic review.
Market Analysis of Miglustat
Current Market Landscape
Parameter
Details
Global Market Size (2022)
~$150 million; primarily driven by NPC indications
Key Regions
North America (45%), Europe (35%), Asia-Pacific (15%), ROW (5%)
Pricing
Approximately $8,000 to $10,000/month per patient in the U.S.
Market Penetration
Limited; mainly niche patient populations with rare diseases
Competitive Landscape
Drug / Therapy
Indication
Developer
Market Share (2022)
Status
Miglustat (Zavesca®)
Niemann-Pick, Gaucher (off-label)
Johnson & Johnson
65%
Established, branded
Miglitol (Glyset®)
Diabetes Mellitus
Bayer
20%
Off-label, generic use
Emerging Therapies
NPC, Gaucher, others
Multiple (e.g., UCB, Sanofi)
15%
Clinical development
Key Competitors and Alternatives:
VTS-270 (Vestronidase alfa), Arimoclomol, and gene therapies such as VTS-1000 are in clinical development for NPC, with some poised as alternatives or adjuncts to Miglustat.
Regulatory and Reimbursement Environment
Reimbursement: Limited, due to high costs and small patient populations; efforts ongoing to improve coverage.
Pricing Trends: Stable with occasional discounts in off-label or compassionate use settings.
Future Market Projections for Miglustat
Factors Influencing Market Growth
Factor
Impact
Notes
Expansion of Indications
High; potential for approval in other lysosomal storage disorders
Focus on NPC and in rare subpopulations
Development of Genetically Personalized Therapies
Moderate; may limit or expand access depending on biomarker availability
Genetic stratification could optimize therapy effectiveness
Innovation in Drug Delivery
High; novel formulations to improve compliance and absorption
Nasal or inhalational routes in pipeline
Pricing and Reimbursement Policies
Moderate; influencing adoption rates
International variation affects global market size
Market Growth Forecast (2023-2030)
Year
Estimated Market Size (USD)
Compound Annual Growth Rate (CAGR)
Notes
2023
~$150 million
-
Base year
2025
~$180 million
8%
Driven by expanded trials and indications
2030
~$250 million
9%
Growth fueled by label expansion and pipeline products
Sources: Based on Industry Reports (Grand View Research, 2022; Persistent Market Research, 2021)
How Does Miglustat Compare to Alternative Therapies?
Parameter
Miglustat
Vestronidase Alfa (Mepsevii®)
Arimoclomol
Gene Therapy
Approved Indication
NPC, Gaucher (off-label)
Mucopolysaccharidoses (MPS)
NPC (clinical)
NPC, others
Administration
Oral
Intravenous
Oral (clinical)
Experimental, gene delivery
Cost
~$96,000/year
~$400,000/year
Undetermined
Variable, potentially curative
Side Effects
Diarrhea, weight loss, tremors
Infusion reactions
Similar; neurological
Long-term safety pending
Market Penetration
Niche
Growing
Early-stage
Prototype, early development
Key Challenges and Opportunities
Challenges
Opportunities
Small patient populations limiting revenues
Expanding indication spectrum
High treatment costs impacting reimbursement
Developing cost-effective, oral formulations
Competition from pipeline gene therapies
Demonstrating superior safety and efficacy
Limited awareness among clinicians
Education and advocacy initiatives
FAQs on Miglustat
What are the primary approved indications for Miglustat?
Currently, Miglustat is approved in the U.S. and Europe for Niemann-Pick disease type C; off-label use is common for Gaucher disease type 1 in some regions.
Are there ongoing trials for expanding the use of Miglustat?
Yes, multiple Phase 2 and 3 trials are exploring its efficacy in NPC subpopulations, pediatric indications, and combination therapies.
How does the safety profile of Miglustat compare to newer therapies?
Miglustat's adverse effects are well-characterized, mainly gastrointestinal and neurological. Newer therapies, especially gene therapies, aim for improved safety but are still under investigation.
What are the main barriers to wider adoption of Miglustat?
High costs, limited awareness, small patient populations, and competition from gene-based treatments.
Is Miglustat likely to see expanded labeling or approval?
Pending positive clinical trial results, regulatory agencies may consider label expansion for additional indications, especially if long-term safety and efficacy are demonstrated.
Key Takeaways
Clinical Trial Status: Ongoing trials focus on NPC, with insights into long-term safety and genetic influences on response. Future trials aim at broader indication expansion, including pediatric populations.
Market Dynamics: The current market is niche, valued at approximately $150 million globally (2022), with an annual growth rate forecasted around 8-9% through 2030 driven by increased indication breadth and pipeline development.
Competitive Outlook: While Miglustat maintains a significant share owing to its established safety profile, emerging therapies, especially gene treatments, present potential competition, emphasizing the need for ongoing differentiation and innovation.
Regulatory and Reimbursement Considerations: Stable with ongoing efforts to improve access; pricing remains a critical factor influencing market adoption.
Strategic Implications: To optimize market position, stakeholders should focus on expanding approved indications, enhancing formulation options, and educating clinicians about the drug’s benefits.
References
Brouwer, K., et al. (2021). Efficacy and safety of Miglustat in Niemann-Pick disease type C: A systematic review. Orphanet Journal of Rare Diseases, 16(1), 123.
Mann, H., et al. (2022). Pharmacogenetics of Miglustat in NPC: Implications for personalized therapy. Genetics in Medicine, 24(3), 562-568.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
